Home › Crohn's Disease › Pennsylvania
Crohn's Disease clinical trials in Pennsylvania
23 studies for Crohn's Disease are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Penn State University Milton S. Hershey Medical Center ( Site 5102), Hershey
- Thomas Jefferson University Hospital ( Site 5133), Philadelphia
- Frontier Clinical Research, LLC ( Site 5098), Uniontown
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 25, 2026 · NCT05923073Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 265904, Philadelphia
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Frontier Clinical Research, Uniontown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Susquehanna Research Group, Harrisburg
- Penn State Milton S Hershey Medical Ctr, Hershey
- University of Pennsylvania, Philadelphia
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Thomas Jefferson University - Medicine/GI and Hepatology, Philadelphia
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Penn State Milton S. Hershey Medical Center-Site Number: 8400066, Hershey
- University of Pennsylvania School of Medicine-Site Number: 8400072, Philadelphia
- The Allegheny Health Network (AHN) Center for Digestive Health-Site Number: 8400107, Pittsburgh
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University of Pennsylvania School of Medicine-Site Number: 8400072, Philadelphia
- The Allegheny Health Network (AHN) Center for Digestive Health-Site Number: 8400107, Pittsburgh
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Children's Hospital of Philadelphia (CHOP), Philadelphia
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Allegheny Health Network, Wexford
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Aug 24, 2026 · NCT05509777Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Children's Hospital of Philadelphia - Main /ID# 262197, Philadelphia
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 24, 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Penn State Health Milton South Hershey Medical Center, Hershey
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Children's Hospital of Philadelphia, Philadelphia
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Children's Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Susquehanna Research Group, LLC, Harrisburg
- UPMC, Pittsburgh
- Frontier Clinical Research, LLC, Uniontown
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Apr 27, 2026 · NCT06456593COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
- University of Pittsburgh Medical Center, Children's Hospital, Pittsburgh
RecruitingObservational study
Ages 1 to 18 · All sexes · Updated Apr 17, 2026 · NCT07198113A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400009, Harrisburg
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Mar 27, 2026 · NCT06958536Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
RecruitingObservational study
2 Months – 60 Years · All sexes · Updated Jan 13, 2026 · NCT04528355Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 2
2 Months – 55 Years · All sexes · Updated Dec 15, 2025 · NCT01962415Autologous Stem Cell Transplantation for Crohn's Disease
- UPMC Prebyterian- Adult Gastroenterology, Pittsburgh
- Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team, Pittsburgh
RecruitingPhase 1/2
Ages 10 to 60 · All sexes · Updated Dec 15, 2025 · NCT00692939Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
- Children's Hospital of Philadelphia, Philadelphia
Recruiting
Ages 8 to 21 · All sexes · Updated Jun 12, 2025 · NCT06216899From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.